Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Botanix Pharmaceuticals Limited
  6. News
  7. Summary
    BOT   AU000000BOT2

BOTANIX PHARMACEUTICALS LIMITED

(BOT)
  Report
Delayed Quote. Delayed Australian Stock Exchange - 01/21 12:10:21 am
0.068 AUD   -1.45%
01/202022 EDISON OPEN HOUSE : Global Healthcare
PU
01/13BOTANIX PHARMACEUTICALS : DEAL NEWS | Pfizer enters CBD market
PU
2021AMR : the next global pandemic?
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Botanix Pharmaceuticals : Investor Roadshow Presentation

12/07/2021 | 11:52pm EST

Botanix has today released an updated corporate presentation to the ASX, to support a non-deal investor roadshow underway this week.

The latest developments in our antimicrobial resistance (AMR) and dermatology R&D programs, include:

  • Progress with our BTX1801 antimicrobial program and plans for Phase 2 clinical studies in early 2022
  • Advancement of our BTX1702 clinical trial for the treatment of rosacea
  • Acceleration of our canine BTX1204A dermatitis study

Click here to view the presentation.

Disclaimer

Botanix Pharmaceuticals Ltd. published this content on 08 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2021 04:51:10 UTC.


ę Publicnow 2021
All news about BOTANIX PHARMACEUTICALS LIMITED
01/202022 EDISON OPEN HOUSE : Global Healthcare
PU
01/13BOTANIX PHARMACEUTICALS : DEAL NEWS | Pfizer enters CBD market
PU
2021AMR : the next global pandemic?
PU
2021BOTANIX PHARMACEUTICALS : Investor Roadshow Presentation
PU
2021BOTANIX PHARMACEUTICALS : Roadshow Presentation
PU
2021BOTANIX PHARMACEUTICALS : ANTIMICROBIAL AWARENESS WEEK 18-24 November 2021
PU
2021BOTANIX PHARMACEUTICALS : MEET THE TEAM | Lynda Berne, Head of Commercial
PU
2021BOTANIX PHARMACEUTICALS : Says Skin Condition Canine Study Underway; Shares Up More than 4..
MT
2021Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program
CI
2021Botanix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 3..
CI
More news
Financials
Sales 2021 6,89 M 4,95 M 4,95 M
Net income 2021 -3,33 M -2,40 M -2,40 M
Net cash 2021 21,3 M 15,3 M 15,3 M
P/E ratio 2021 -23,4x
Yield 2021 -
Capitalization 66,2 M 47,7 M 47,6 M
EV / Sales 2020 1,81x
EV / Sales 2021 8,21x
Nbr of Employees -
Free-Float -
Chart BOTANIX PHARMACEUTICALS LIMITED
Duration : Period :
Botanix Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BOTANIX PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Managers and Directors
Vincent P. Ippolito Executive Chairman & President
H. Bill Bosch Executive Director & Chief Scientific Officer
Clarence L. Young Chief Medical Officer
Stewart James Washer Non-Executive Director
Matthew Callahan Executive Director
Sector and Competitors